Zhe Feng1,2, Hua-Long Li1,2, Wei-Jie Bei1,2, Xiao-Sheng Guo1,2, Kun Wang1,2,3, Shi-Xin Yi1, De-Mou Luo1, Xi-da Li1, Shi-Qun Chen1,2, Peng Ran1, Peng-Yuan Chen1,2, Sheikh Mohammed Shariful Islam4, Ji-Yan Chen1,2, Yong Liu1,2, Ying-Ling Zhou1,2. 1. Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. 2. School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. 3. Department of Graduate School (Wang), Southern Medical University, Guangzhou, Guangdong, China. 4. The George Institute for Global Health (Islam), University of Sydney, Camperdown, New South Wales, Australia.
Abstract
BACKGROUND: There is no consistent evidence to suggest the association of plasma lipoprotein(a) (Lp[a]) with long-term mortality in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). HYPOTHESIS: Level of Lp(a) is associated with long-term mortality following CAG or PCI. METHODS: We enrolled 1684 patients with plasma Lp(a) data undergoing CAG or PCI between April 2009 and December 2013. The patients were divided into 2 groups: a low-Lp(a) group (Lp[a] <16.0 mg/dL; n = 842) and a high-Lp(a) group (Lp[a] ≥16.0 mg/dL; n = 842). RESULTS: In-hospital mortality was not significantly different between the high and low Lp(a) groups (0.8% vs 0.5%, respectively; P = 0.364). During the median follow-up period of 1.95 years, the high-Lp(a) group had a higher long-term mortality than did the low-Lp(a) group (5.8% vs 2.5%, respectively; P = 0.003). After adjustment of confounders, multivariate Cox regression analysis revealed that a higher Lp(a) level was an independent predictor of long-term mortality (hazard ratio: 1.96, 95% confidence interval: 1.07-3.59, P = 0.029). CONCLUSIONS: Our data suggested that an elevated Lp(a) level was significantly associated with long-term mortality following CAG or PCI. However, additional larger multicenter studies will be required to investigate the predictive value of Lp(a) levels and evaluate the benefit of controlling Lp(a) levels for patients undergoing CAG or PCI.
BACKGROUND: There is no consistent evidence to suggest the association of plasma lipoprotein(a) (Lp[a]) with long-term mortality in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). HYPOTHESIS: Level of Lp(a) is associated with long-term mortality following CAG or PCI. METHODS: We enrolled 1684 patients with plasma Lp(a) data undergoing CAG or PCI between April 2009 and December 2013. The patients were divided into 2 groups: a low-Lp(a) group (Lp[a] <16.0 mg/dL; n = 842) and a high-Lp(a) group (Lp[a] ≥16.0 mg/dL; n = 842). RESULTS: In-hospital mortality was not significantly different between the high and low Lp(a) groups (0.8% vs 0.5%, respectively; P = 0.364). During the median follow-up period of 1.95 years, the high-Lp(a) group had a higher long-term mortality than did the low-Lp(a) group (5.8% vs 2.5%, respectively; P = 0.003). After adjustment of confounders, multivariate Cox regression analysis revealed that a higher Lp(a) level was an independent predictor of long-term mortality (hazard ratio: 1.96, 95% confidence interval: 1.07-3.59, P = 0.029). CONCLUSIONS: Our data suggested that an elevated Lp(a) level was significantly associated with long-term mortality following CAG or PCI. However, additional larger multicenter studies will be required to investigate the predictive value of Lp(a) levels and evaluate the benefit of controlling Lp(a) levels for patients undergoing CAG or PCI.
Authors: Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245
Authors: K E Sorensen; D S Celermajer; D Georgakopoulos; G Hatcher; D J Betteridge; J E Deanfield Journal: J Clin Invest Date: 1994-01 Impact factor: 14.808
Authors: Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen Journal: Eur Heart J Date: 2010-10-21 Impact factor: 29.983
Authors: Jian-Jun Li; Khung Keong Yeo; Kathyrn Tan; Junya Ako; Rungroj Krittayaphong; Ru San Tan; Philip E Aylward; CarolynS P Lam; Sang Hong Baek; Jamshed Dalal; Alan Fong; Yi-Heng Li; Richard C O'Brien; Si Ya Natalie Koh; Daniel J Scherer; Hayato Tada; Vernon Kang; Julie Butters; Stephen J Nicholls Journal: Am J Prev Cardiol Date: 2020-11-08